We are focused on advancing a new generation of treatments that bring the rigor of human biotechnology into veterinary care, helping veterinarians do more for the animals and families they serve.

VTX-304 is a bispecific antibody designed to treat osteoarthritis by addressing both pain signaling and cartilage degradation within a single therapy, with the aim of moving beyond symptom management to potentially the first and only disease-modifying osteoarthritis drug (DMOAD).

VTX-301/302 is an immunotherapy combination designed to bring a more targeted approach to cancer treatment in pets. The program aims to enhance anti-tumor activity above and beyond the historically low response rates seen with checkpoint inhibitors alone.